Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there?

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 412-414

  Tillmann, Hans Ludger ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; BOCEPREVIR; INTERLEUKIN 28B; LAMIVUDINE; MACROGOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

DRUG EFFICACY; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84874114351     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.12.007     Document Type: Editorial

References (30)

1. C.T. Bock, H.L. Tillmann, J. Torresi, J. Klempnauer, S. Locarnini, and M.P. Manns Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation Gastroenterology 122 2002 264 273
2. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, and Z. Goodman Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
3. K.F. Murray, L. Szenborn, J. Wysocki, S. Rossi, A.C. Corsa, and P. Dinh Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B Hepatology 2012 10.1002/hep. 25818 [Epub ahead of print]
4. A.M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, Z. Goodman, and S.M. Banks A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis J Hepatol 11 Suppl. 1 1990 S36 S42
5. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
6. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426 1432
7. M.P. Manns, J.G. McHutchison, S. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
8. M.W. Fried, M.L. Schiffman, and R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection N Engl J Med 347 2002 975 982
9. T. Awad, K. Thorlund, G. Hauser, D. Stimac, M. Mabrouk, and C. Gluud Peginterferon alpha-2a is associated with higher sustained virological response than Peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials Hepatology 51 2010 1176 1184
10. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
11. T. Minami, T. Kishikawa, M. Sato, R. Tateishi, H. Yoshida, and K. Koike Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C J Gastroenterol 12 2012 12 [Epub ahead of print]
12. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
13. N.H. Afdhal, J.G. McHutchison, S. Zeuzem, A. Mangia, J.M. Pawlotsky, and J.S. Murray Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 53 2011 336 345
14. A.U. Neumann, S. Pianko, S. Zeuzem, E.M. Yoshida, Y. Benhamou, and M. Mishan Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C J Hepatol 51 2009 21 28
15. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
16. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
17. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
18. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
19. A. Aronsohn, and D. Jensen Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology 53 2011 1789 1791
20. C. Hezode, C. Dorival, F. Zoulim, D.G. Larrey, S. Pol, and P. Cacoub Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting Hepatology 56 Suppl. 2012 217A
21. A.L. Aloia, S. Locarnini, and M.R. Beard Antiviral resistance and direct-acting antiviral agents for HCV Antivir Ther 17 2012 1147 1162
22. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
23. M. Aus dem Siepen, C. Oniangue-Ndza, M. Wiese, S. Ross, M. Roggendorf, and S. Viazov Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon Virus Res 125 2007 109 113 [Epub 2007 Jan 24]
24. Z. Makowska, F.H. Duong, G. Trincucci, D.F. Tough, and M.H. Heim Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo Hepatology 53 2011 1154 1163
25. E. Poordad, E. Lawitz, K.V. Kowdley, G.T. Everson, B. Freilich, and D. Cohen 12-Week interferon-free regimen of ABT-450/R +ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naïve HCV genotype-1-infected subject and 47% of previous non-responders J Hepatol 56 Suppl. 2 2012 S549 S550
26. E.J. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R. Hindes Once daily sofosbuvir (GS-7977) Plus Ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON Trial Hepatology 56 Suppl. 2012 306A
27. S. Bruno, J.M. Vierling, R. Esteban, L.M. Nyberg, H. Tanno, and Z. Goodman Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis J Hepatol 58 2013 479 487
28. G.R. Foster, S. Zeuzem, P. Andreone, S. Pol, E.J. Lawitz, and M. Diago Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure J Hepatol 2012 10.1016/j.jhep. 2012.11.013 [Epub ahead of print]
29. J. Guedj, and A.S. Perelson Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration Hepatology 53 6 2011 1801 1808
30. Thompson AJ, Shiffman ML, Rossaro L, Ghalib R, Han SHB, Beavers KL, et al. Six Weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR4 rates in genotype 1 IL28B CC treatment naïve HCV patients: Interim Results of a prospective, randomized trial.